Undisclosed anti TDP-43 antibody / AC Immune - LARVOL DELTA

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) - "IND/CTA filing for small molecule NLRP3 inhibitor ACI-19764 and the start of IND-enabling studies for Morphomer-Tau aggregation inhibitor both expected by year-end...'We are now moving towards multiple value-inflection points. Further interim results from Part 1 of the VacSYn trial of ACI-7104.056, our wholly owned anti-alpha-synuclein active immunotherapy for Parkinson’s disease, are expected this quarter.'...'This technology also powers our ACI-24.060 anti-Abeta active immunotherapy program, for which additional results are expected in H1 next year.'...TDP-43-PET tracer: Initial Phase 1 readout in genetic frontotemporal dementia (FTD): Q4 2025....ACI-15916 a-syn-PET tracer: Phase 1 readout in Parkinson’s disease (PD): Q4 2025."

Clinical data • IND • Alzheimer's Disease • Frontotemporal Lobar Degeneration • Parkinson's Disease

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire) - "ACI-24.060 anti-Abeta active immunotherapy: Additional interim safety and immunogenicity data from AD cohorts of ABATE study expected in Q4 2023; First Abeta-PET data on amyloid plaque reduction in AD following 6 months of treatment expected in H1 2024; ACI-7104.056 anti-a-syn active immunotherapy: Completion of cohort 1 enrollment and initial safety findings in the Phase 2 VacSYn study in PD expected by year-end; ACI-35.030 anti-pTau active immunotherapy: Initiation of next trial in AD expected in Q4 2023 (to be followed by a milestone payment); Anti-TDP-43 antibody: Advancement of candidate into preclinical development (tox) expected in Q4 2023..."

New trial • P1/2 data • P2 data • Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease

AC Immune Showcasing Precision Medicine Programs at AAIC 2023 (GlobeNewswire) - "AC Immune SA...today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC 2023), taking place in Amsterdam, The Netherlands, on July 16-20, 2023...The presentations will include a poster detailing the design of the Phase 1b/2 ABATE trial evaluating the ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy in patients with Alzheimer’s disease and individuals with Down syndrome. In addition, AC Immune scientists have organized a 'Perspectives Session' focused on TDP-43 proteinopathy in neurodegenerative diseases. Finally, an oral presentation will be given showing detailed data on ACI-12589, AC Immune’s novel positron emission tomography (PET) tracer targeting alpha-synuclein."

Biomarker • Clinical protocol • Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 (GlobeNewswire) - "AC Immune SA...announced prestigious new grants from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases."

Financing • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Frontotemporal Lobar Degeneration • Parkinson's Disease

AC Immune SA (ACIU) Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases (Streetinsider.com) - "AC Immune...today outlined new preclinical data that will be presented at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD)...Data from the Company’s wholly owned, first-in-class therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) are described during four oral and e-poster presentations."

Preclinical • CNS Disorders • Proteinopathy • Tauopathies And Synucleinopathies

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD 2021 Virtual Conference (GlobeNewswire) - AC Immune...today announced that four new data presentations will be delivered at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM), taking place virtually from March 9–14, 2021. The presentations will highlight preclinical results from the Company’s wholly-owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) for neurodegenerative diseases.

Biomarker • Preclinical • CNS Disorders • Parkinson's Disease • Proteinopathy • Tauopathies And Synucleinopathies

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development (GlobeNewswire) - "AC Immune...and WuXi Biologics...today unveiled plans to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications....This next phase of the strategic partnership between the companies builds on the industry leading know-how of AC Immune’s proprietary drug discovery and development platforms and WuXi Biologics’ expertise in manufacturing innovative biologics."

Licensing / partnership • Amyotrophic Lateral Sclerosis • CNS Disorders • Frontotemporal Lobar Degeneration

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent (GlobeNewswire) - "Grant from the ‘EU Joint Programme – Neurodegenerative Disease Research’ (JPND) provides €1.45M in funding for the program...Advancement of AC Immune’s TDP-43 PET tracer could deliver the world’s first imaging agent capable of accurately detecting and monitoring the progression of a wide range of TDP-43-related neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP)..."

Grant • Amyotrophic Lateral Sclerosis • CNS Disorders • Frontotemporal Lobar Degeneration

AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration (GlobeNewswire) - “AC Immune SA…announced the initiation of investigational new drug (IND)-enabling studies for the Company’s first-in-class therapeutic antibody targeting TDP-43 (TAR DNA-binding protein 43). The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications…the first TDP-43 targeted therapeutic approach for treating conditions such as amyotrophic lateral sclerosis (ALS)…”

New trial • Amyotrophic Lateral Sclerosis • CNS Disorders

AC Immune reports Q1 2020 financial results and provides business update (GlobeNewswire) - "Advanced a lead anti-alpha-synuclein therapeutic antibody candidate into preclinical development based on new proof-of-concept data presented at AAT-AD/PD^TM....2020 Preclinical Milestones: Alpha-synuclein antibody: started investigational new drug (IND)-enabling studies for lead candidate in Q1 (achieved); Anti-TDP-43 antibody: declare clinical lead and start IND-enabling studies in Q2; Alpha-synuclein small molecule: identify first biologically active small molecule in Q2; Alpha-synuclein imaging agent: advance third generation candidate to clinical stage in Q4."

IND • New molecule • Preclinical • CNS Disorders • Parkinson's Disease • Tauopathies And Synucleinopathies

AC Immune presents the latest preclinical data on novel drug targets for neurodegenerative diseases (GlobeNewswire, AC Immune SA) - "AC Immune SA...today outlined new preclinical data that will be presented at this year’s first ever online AAT-AD/PD™ Focus Meeting from April 2–5, 2020. The presentations describe proof-of-concept preclinical data for lead candidates in AC Immune’s therapeutic and diagnostic programs targeting TDP-43 and alpha-synuclein; A lead anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat Parkinson’s disease and other synucleinopathies."

Biomarker • Clinical data • Preclinical